Trial
NCT06046482
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
M.D. Anderson Cancer Center
Collaborators
Gilead Sciences
Condition
Head Neck
Intervention
Pembrolizumab
Why stopped
Slow Accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-22